Liraglutide: A review of its use in type 2 diabetes mellitus

Drugs

Volumn 69, Issue 14, 2009, Pages 1985-2004

  Croom, Katherine F ^a   McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ATORVASTATIN; DIGOXIN; ETHINYLESTRADIOL; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; GRISEOFULVIN; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; LEVONORGESTREL; LIRAGLUTIDE; LISINOPRIL; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; NATEGLINIDE; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICTOZA; VILDAGLIPTIN;

BODY WEIGHT; CELL FUNCTION; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; JAPANESE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; PULSE RATE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; STOMACH EMPTYING; THERAPY EFFECT; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME;

EID: 70349095558     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11201060-000000000-00000     Document Type: Review

References (68)

1. World Health Organization. The global burden of disease: 2004 update [online]. Available from URL: http:// www.who.int/healthinfo [Accessed 2009 Feb 26]
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009 Jan; 32 Suppl. 1: S62-S67
3. American Association of Clinical Endocrinologists Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13 Suppl. 1: 3-68
4. Pratley RE. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase inhibitors for type 2 diabetes. Medscape J Med 2008; 10 (7): 171
5. Vilsbøll T, Knop FK. Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus. Biodrugs 2008; 22 (4): 251-257
6. Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 2005; 4 (6): 361-370 (Pubitemid 41751172)
7. Vilsbøll H, Agersø H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88 (1): 220-224
8. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43 (9): 1664-1669
9. Irie S, Matsumura Y, Zdravkovic M, et al. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily humanGLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Int J Clin Pharmacol Ther 2008 Jun; 46 (6): 273-279
10. Steensgaard DB, Thomsen JK, Olsen HB, et al. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide [abstract no. 552-P]. Diabetes 2008; 57 Suppl. 1: A164
11. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002 Feb; 51 (2): 424-429
12. Flint A, Kapitza C, Hindsberger C, et al. The once-daily human GLP-1 analogue liraglutide improves both absolute and baseline corrected postprandial glucose levels [abstract no. 556-P]. Diabetes 2008 Jun; 57 Suppl. 1: A165
13. Harder H, Nielsen L, Tu DT, et al. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004 Aug; 27 (8): 1915-1921
14. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211)markedly improves 24-h glycemia and a- andb-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004 May; 53 (5): 1187-1194
15. Seino Y, Rasmussen MF, Zdravkovic M, et al. Dosedependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008 Aug; 81 (2): 161-168
16. Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007 Jun; 30 (6): 1608-1610
17. Nauck MA, El-Ouaghlidi A, Hompesch M, et al. No impairment of hypoglycaemia counterregulation via glucagon with the long-acting GLP-1 derivative, NN2211, in subjects with type 2-diabetes [abstract no. 824]. Diabetologia 2003; 46 Suppl. 2: A285
18. Horowitz M, Flint A, Doran S, et al. Effects of the oncedaily human GLP-1 analogue liraglutide on appetite and energy intake in type 2 diabetes [abstract no. 889]. Diabetologia 2008 Sep; 51 Suppl. 1: S355
19. Vilsbøll T, Brock B, Perrild H, et al. Liraglutide, a oncedaily human GLP-1 analogue, improves pancreatic b-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008 Feb; 25 (2): 152-156
20. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores b-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003 Jul; 52 (7): 1786-1791
21. Marre M, Shaw J, Brä ndle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009 Mar; 26 (3): 268-278
22. Mari A, Degn K, Brock B, et al. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on b-cell function in normal living conditions. Diabetes Care 2007 Aug; 30 (8): 2032-2033
23. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2-study. Diabetes Care 2009; 32 (1): 84-90
24. Flint A, Kapitza C, Hindsberger C, et al. The once-daily human GLP-1 analogue liraglutide decreases postprandial hunger and energy intake [abstract no. 555-P]. Diabetes 2008 Jun; 57 Suppl. 1: A165
25. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009 Jul; 32 (7): 1224-1230
26. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Diabetologia. Epub 2009 Aug 14
27. Jendle J, Nauck MA, Matthews D, et al. The reduction of body weight with liraglutide, a once-daily human GLP-1 analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat [abstract no. 797]. Diabetologia 2008 Sep; 51 Suppl. 1: S318
28. Colagiuri S, Frid A, Zdravkovic M, et al. Liraglutide, a human GLP-1 analogue, reduces systolic blood pressure in subjects with type 2 diabetes [abstract no. 899]. Diabetologia 2008 Sep; 51 Suppl. 1: S360
29. Courrèges J-P, Vilsbøll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide- 1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 2008 Sep; 25 (9): 1129-1131
30. Dear AE, Liu H, Knudsen LB, et al. Liraglutide inhibits hyperglycaemia induced expression of PAI-1 and vascular adhesion molecules in an in vitro model of endothelial cell dysfunction [abstract no. 893]. Diabetologia 2008 Sep; 51 Suppl. 1: S356
31. Sprenger C, Khutoryansky N, Chatterjee DJ, et al. Liraglutide does not affect cardiac repolarization [abstract no. 2103-PO]. Diabetes 2008 Jun; 57 Suppl. 1: 581
32. ShimodaM,Kanda Y, Tawaramoto K, et al. The once-daily human GLP-1 analogue liraglutide preserves pancreatic beta cells in diabetic db/db mice through both acute and chronic actionmechanisms [abstract no. 511]. Diabetologia 2008 Sep; 51 Suppl. 1: S210
33. Bregenholt S, Møldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits b-cell apoptosis in vitro. Biochem Biophys Res Commun 2005 May 6; 330 (2): 577-584
34. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009 Apr; 58 (4): 975-983
35. US FDA. Liraglutide (injection) for the treatment of patients with type 2 diabetes: NDA 22-341 briefing document [online]. Available from URL: http://www.fda.gov/ohrms/ dockets/ac/09/briefing/2009-4422b2-02-NovoNordisk.pdf [Accessed 2009 Jun 23]
36. Elbrønd B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002 Aug; 25 (8): 1398-1404 (Pubitemid 41071152)
37. Jonker DM, Watson E, Toft AD, et al. Pharmacokinetic modelling of the once-daily human glucagon-like peptide-1 analogue, liraglutide, in healthy volunteers and comparison to exenatide [abstract no. 0850].
38. Diabetologia 2007 Sep; 50 Suppl. 1: 351-2. Plus poster presented at the 43rd AnnualMeeting of the European Association for the Study of Diabetes; 2007 Sep 18-21; Amsterdam
39. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002 Feb; 45 (2): 195-202
40. Triplitt C, Wright A, Chiquette E. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetesmellitus. Pharmacotherapy 2006; 26 (3): 360-374
41. Kapitza C, Flint A, Spitzer H, et al. The effect of three different injection sites on the pharmacokinetics of the oncedaily human GLP-1 analogue liraglutide [abstract no. 2146-PO]. Diabetes 2008 Jun; 57 Suppl. 1: A593
42. Bjørnsdottir I, Olsen A, Larsen U, et al. Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subject and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase [abstract no. 891]. Diabetologia 2008 Sep; 51 Suppl. 1: S356
43. Damholt B, Golor G, Wierich W, et al. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon- like peptide-1 analogue liraglutide. J Clin Pharmacol 2006 Jun; 46 (6): 635-641
44. Jacobsen LV, Hindsberger C, Robson R, et al. Pharmacokinetics of the long-acting humanGLP-1 analogue liraglutide in subjects with renal impairment [abstract no. 0852].
45. Flint A, Nazzal K, Jagielski P, et al. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide [abstract no. 0545-P plus poster]. 67th Scientific Sessions of the American Diabetes Association; 2007 Jun 22-26; Chicago (IL)
46. Malm-Erjefä lt M, Brøndsted L, Zdravkovic M. The effect of liraglutide on intragastric pH in healthy human subjects [abstract no. 2144-PO]. Diabetes 2008 Jun; 57 Suppl. 1: A593
47. Zdravkovic M, Ekblom M, Brøndsted L, et al. The effect of liraglutide on the absorption pharmacokinetics of concomitant oral drugs with different solubility and permeability properties in healthy subjects [abstract no. 890]. Diabetologia 2008 Sep; 51 Suppl. 1: S355
48. Kapitza C, Flint A, Hindsberger C, et al. The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol [abstract no. 2145-PO]. Diabetes 2008 Jun; 57 Suppl. 1: A593
49. Jacobsen L, Brøndsted L,Vouis J, et al.Arandomized, doubleblind, cross-over trial investigating the effect of liraglutide on the absorption of an oral contraceptive drug [abstract no. 2047-PO]. Diabetes 2008 Jun; 57 Suppl. 1: A566
50. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009 Jul 4; 374 (9683): 39-47
51. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, paralleltreatment trial. Lancet 2009 Feb 7; 373 (9662): 473-481
52. Seino Y, Rasmussen MF, Katayama Y, et al. Liraglutide is statistically superior to glibenclamide at controlling glycemia and weight, with low hypoglycemic risk, and improves beta-cell function in Japanese subjects with T2D [abstract no. 536-P]. 69th Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)
53. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004 Jun; 27 (6): 1335-1342
54. Feinglos MN, Saad MF, Pi-Sunyer FX, et al. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med 2005 Aug; 22 (8): 1016-1023
55. Nauck MA, Hompesch M, Filipczak R, et al. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006 Sep; 114 (8): 417-423
56. American Diabetes Association. Standards ofmedical care in diabetes: 2009. Diabetes Care 2009 Jan; 32 Suppl. 1: S13-S61
57. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006 Jun; 23 (6): 579-593
58. Bode BW, Hale PM, Hammer M, et al. Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide or glimepiride [abstract no. 894]. Diabetologia 2008 Sep; 51 Suppl. 1: S357
59. Garber A, Henry R, Ratner R, et al. Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in A1c, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 mono 2-year results [abstract no. 162-OR]. 69th Scientific Sessions of theAmerican Diabetes Association; 2009 Jun 5-9; New Orleans (LA)
60. Vaag A, Nauck MA, Brandle M, et al. Liraglutide, a human GLP-1 analogue, substantially reduces HbA1c in subjects with type 2 diabetes, irrespective of HbA1c at baseline [abstract no. 149]. Diabetologia 2008 Sep; 51 Suppl. 1: S68-S69
61. Matthews DR, Marre M, Le-Thi TD, et al. Liraglutide, a human GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes [abstract no. 892]. Diabetologia 2008 Sep; 51 Suppl. 1: S356
62. Schmitz O, Russell-Jones D, Shaw J, et al. Liraglutide, a human GLP-1 analogue, reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline [abstract no. 888]. Diabetologia 2008 Sep; 51 Suppl. 1: S354
63. Frid A, Nauck MA, Hermansen K, et al. Evaluation of patient reported outcomes in subjects with type 2 diabetes treated with the once-daily human GLP-1 analog liraglutide or glimepiride, both as add-on to metformin [abstract no. 2080-PO]. Diabetes 2008 Jun; 57 Suppl. 1: A574-A575
64. European Medicines Agency. Victoza (liraglutide): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/ victoza/H-1026-PI-en.pdf [Accessed 2009 Aug 26]
65. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008 Jan; 31 (1): 173-175
66. National Institute forHealth and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes (clinical guideline 66) [online]. Available from URL: http://guidance. nice.org.uk/CG66/Guidance/pdf/English [Accessed 2009 Feb 28]
67. Cvetković RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).Drugs 2007; 67 (6): 935-954
68. Electronic Medicines Compendium. Byetta 5 or 10mg solution for injection: summary of product characteristics [online]. Available from URL: http://emc.medicines.org. uk/document.aspx?documentId=19257 [Accessed 2009 Jun 23]